Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 45963-733

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 45963-733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure of Doxorubicin hydrochloride, showing its complex arrangement of fused rings with multiple hydroxyl, methoxy, amino, and carbonyl functional groups, along with the associated hydrochloride (HCl) moiety.*

FDA Label Image

2 (Image 2)

A meta-analysis forest plot showing hazard ratios with 95% confidence intervals comparing doxorubicin-based treatments versus CMF across six clinical trials. Each trial is represented by a square and horizontal line indicating the confidence interval, with a diamond summarizing the combined result. A vertical dashed line marks the boundary of non-inferiority with CMF at a hazard ratio of 1.06.*

FDA Label Image

3 (Image 3)

A forest plot chart displaying hazard ratios with 95% confidence intervals from six clinical trials comparing Doxorubicin-based treatments to CMF. The horizontal axis measures hazard ratio values from 0.0 to 2.0, indicating relative efficacy. Individual trial estimates are depicted as squares with confidence lines, and a combined summary is shown as a diamond shape at the bottom.*

FDA Label Image

1 (Image 4)

Packaging label for Doxorubicin Hydrochloride Injection USP 10 mg/5 mL (2 mg/mL) intravenous solution by Actavis Pharma, Inc. The label shows a 5 mL single-dose vial, sterile isotonic solution, nonpyrogenic and preservative-free. It includes warnings about cytotoxicity, severe cellulitis, vesication, and tissue necrosis with extravasation. Manufacturer and serialization details are also visible.*

FDA Label Image

Image 5

Packaging label for Doxorubicin Hydrochloride Injection USP 20 mg/10 mL (2 mg/mL) by Teva Pharmaceuticals USA, Inc. The label indicates it is a sterile isotonic solution for intravenous use, nonpyrogenic and preservative-free, in a 10 mL single-dose vial. It includes warnings about cytotoxicity and severe cellulitis if extravasated, storage instructions, and a barcode.*

FDA Label Image

Image 6

Carton label for Doxorubicin Hydrochloride Injection USP 50 mg/25 mL (2 mg/mL) by Teva Pharmaceuticals USA, Inc. The label indicates a 25 mL single-dose vial for intravenous use, sterile isotonic solution, nonpyrogenic, preservative-free. Contains warnings about cytotoxicity and administration risks, storage instructions, and manufacturing details.*

FDA Label Image

Image 7

Packaging label for Doxorubicin Hydrochloride Injection USP 200 mg/100 mL (2 mg/mL) solution, for intravenous use only. The label shows it is a sterile isotonic, nonpyrogenic, preservative-free 100 mL multi-dose vial distributed by Teva Pharmaceuticals USA, Inc. It includes warnings about severe cellulitis, vesication, tissue necrosis, and a caution that it is a cytotoxic agent. Storage instructions indicate refrigeration between 2° to 8°C and protection from light. Manufactured in Romania by Sindan Pharma SRL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.